Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).

Trial Details

NCT ID
NCT06601296
Phase
PHASE2
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • IMSA101
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Patients must have metastatic ccRCC.
  • Patients must have oligoprogression defined as progression in ≤5 lesions.
  • All oligoprogression lesions must be suitable for radiation.
  • Patients must have at least one site of disease that can be safely injected with IMSA101.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →